Scarica l'app Stockscreener
10.07
5.71%
-0.62
Precedente Chiudi:
$10.69
Aprire:
$10.7
Volume 24 ore:
1.13M
Relative Volume:
0.64
Capitalizzazione di mercato:
$996.17M
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-21.43
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-13.25%
1M Prestazione:
-43.37%
6M Prestazione:
-7.27%
1 anno Prestazione:
-14.21%
Intervallo 1D:
$10.03
$10.73
Intervallo di 1 settimana:
$10.03
$11.80
Portata 52W:
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Confronta SPRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.08 | 1.06B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.30 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.14 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.59 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
747.50 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Chart overlay techniques for tracking ARS Pharmaceuticals Inc.Global Markets & Real-Time Buy Zone Alerts - Newser
Comparing ARS Pharmaceuticals Inc. in custom built stock radarsMarket Risk Report & Risk Managed Investment Strategies - Newser
Intraday pattern recognizer results for ARS Pharmaceuticals Inc.2025 Price Action Summary & Low Risk Entry Point Tips - Newser
When is the best time to exit ARS Pharmaceuticals Inc.Portfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is ARS Pharmaceuticals Inc. forming a bottoming basePortfolio Value Summary & Daily Entry Point Alerts - Newser
What recovery options are there for ARS Pharmaceuticals Inc.Trade Performance Summary & Community Verified Watchlist Alerts - Newser
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA - MSN
What are ARS Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - khodrobank.com
Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential - Investing.com
What is ARS Pharmaceuticals Inc. s debt to equity ratioWeekly Trade Review & Accurate Intraday Trading Signals - khodrobank.com
Short Squeeze: How does ARS Pharmaceuticals Inc. compare to its peersWeekly Trade Summary & Breakout Confirmation Trade Signals - khodrobank.com
What machine learning models say about ARS Pharmaceuticals Inc.July 2025 Movers & Safe Capital Investment Plans - Newser
Using data models to predict ARS Pharmaceuticals Inc. stock movementGap Up & Community Shared Stock Ideas - Newser
Applying Elliott Wave Theory to ARS Pharmaceuticals Inc.Rate Hike & Breakout Confirmation Alerts - Newser
Real time social sentiment graph for ARS Pharmaceuticals Inc.Trend Reversal & Trade Opportunity Analysis - Newser
Can ARS Pharmaceuticals Inc. scale operations efficientlyEarnings Beat & AI Powered Market Entry Strategies - khodrobank.com
Can ARS Pharmaceuticals Inc. be the next market leaderJuly 2025 Volume & Momentum Based Trading Ideas - khodrobank.com
What are ARS Pharmaceuticals Inc.’s growth leversJuly 2025 Recap & Trade Opportunity Analysis Reports - khodrobank.com
How volatile is ARS Pharmaceuticals Inc. stockJuly 2025 Rallies & Risk Controlled Stock Alerts - khodrobank.com
Real time pattern detection on ARS Pharmaceuticals Inc. stockJuly 2025 Price Swings & High Accuracy Buy Signal Tips - Newser
Can ARS Pharmaceuticals Inc. rally from current levelsJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - Newser
Risk vs reward if holding onto ARS Pharmaceuticals Inc.2025 Trading Recap & Intraday High Probability Alerts - Newser
ARS Pharmaceuticals Inc. recovery potential after sell off2025 Market Sentiment & Free Real-Time Market Sentiment Alerts - Newser
Using economic indicators to assess ARS Pharmaceuticals Inc. potentialJuly 2025 Outlook & Fast Entry High Yield Tips - Newser
Will ARS Pharmaceuticals Inc. benefit from seasonalityMarket Performance Report & Low Drawdown Momentum Ideas - khodrobank.com
What drives ARS Pharmaceuticals Inc.’s stock priceJuly 2025 News Drivers & Fast Gain Stock Tips - khodrobank.com
Insider Sell: Is ARS Pharmaceuticals Inc. stock a hidden gemQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - khodrobank.com
Can ARS Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - khodrobank.com
Is ARS Pharmaceuticals Inc. stock trending bullishJuly 2025 Final Week & Free Real-Time Market Sentiment Alerts - khodrobank.com
What moving averages say about ARS Pharmaceuticals Inc.Quarterly Portfolio Report & Precise Entry and Exit Recommendations - Newser
Is ARS Pharmaceuticals Inc. stock a falling knife or bargain buy2025 Price Momentum & Free Expert Verified Stock Movement Alerts - khodrobank.com
How does ARS Pharmaceuticals Inc. compare to its peersBull Run & Expert Approved Momentum Trade Ideas - khodrobank.com
Custom watchlist performance reports with ARS Pharmaceuticals Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Using flow based indicators on ARS Pharmaceuticals Inc.2025 Momentum Check & Expert Verified Movement Alerts - Newser
What’s the outlook for ARS Pharmaceuticals Inc.’s sectorWeekly Stock Recap & Intraday High Probability Setup Alerts - khodrobank.com
Published on: 2025-09-01 14:50:55 - Newser
Does ARS Pharmaceuticals Inc. have strong fundamentalsJobs Report & Advanced Technical Analysis Signals - خودرو بانک
ARS Pharmaceuticals Inc. At Decision Level — Rebound or Resistance2025 Performance Recap & Long-Term Growth Plans - beatles.ru
Quantitative breakdown of ARS Pharmaceuticals Inc. recent moveJuly 2025 Action & Pattern Based Trade Signal System - Newser
Ars Pharmaceuticals Reports Strong Q2 Growth and Global Expansion - TipRanks
How to monitor ARS Pharmaceuticals Inc. with trend dashboardsQuarterly Profit Report & Free Technical Confirmation Trade Alerts - Newser
Analyzing ARS Pharmaceuticals Inc. with multi timeframe charts2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
Analyzing net buyer seller activity in ARS Pharmaceuticals Inc.2025 Key Highlights & Risk Controlled Stock Alerts - Newser
How to interpret RSI for ARS Pharmaceuticals Inc. stockWeekly Risk Report & AI Powered Market Entry Strategies - Newser
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ars Pharmaceuticals Inc Azioni (SPRY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Option Exercise |
1.50 |
12,500 |
18,750 |
22,542 |
| Scott Kathleen D. | Chief Financial Officer |
Aug 21 '25 |
Sale |
15.00 |
12,500 |
187,500 |
10,042 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 20 '25 |
Sale |
14.09 |
37,656 |
530,626 |
1,247,447 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER |
Aug 19 '25 |
Sale |
14.03 |
12,344 |
173,130 |
1,285,103 |
0.23%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):